BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29903928)

  • 41. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
    Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
    Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A CAR RNA FISH assay to study functional and spatial heterogeneity of chimeric antigen receptor T cells in tissue.
    Eichholz K; Li AZ; Diem K; Jensen MC; Zhu J; Corey L
    Sci Rep; 2021 Jun; 11(1):12921. PubMed ID: 34155235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells.
    Xu N; Yang XF; Xue SL; Tan JW; Li MH; Ye J; Lou XY; Yu Z; Kang LQ; Yan ZQ; Yu L; Chen SN; Wang YT
    Biochem Biophys Res Commun; 2022 Mar; 595():54-61. PubMed ID: 35101664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
    Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
    Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of cryopreservation on chimeric antigen receptor T cell functions.
    Xu H; Cao W; Huang L; Xiao M; Cao Y; Zhao L; Wang N; Zhou J
    Cryobiology; 2018 Aug; 83():40-47. PubMed ID: 29908946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
    Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [
    Grzmil M; Qin Y; Schleuniger C; Frank S; Imobersteg S; Blanc A; Spillmann M; Berger P; Schibli R; Behe M
    Theranostics; 2020; 10(24):10861-10873. PubMed ID: 33042258
    [No Abstract]   [Full Text] [Related]  

  • 53. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cell penetrating peptide functionalized perfluorocarbon nanoemulsions for targeted cell labeling and enhanced fluorine-19 MRI detection.
    Hingorani DV; Chapelin F; Stares E; Adams SR; Okada H; Ahrens ET
    Magn Reson Med; 2020 Mar; 83(3):974-987. PubMed ID: 31631402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
    Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
    J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Insights on Droplet Digital PCR-Based Cellular Kinetics and Biodistribution Assay Support for CAR-T Cell Therapy.
    Sugimoto H; Chen S; Minembe JP; Chouitar J; He X; Wang H; Fang X; Qian MG
    AAPS J; 2021 Mar; 23(2):36. PubMed ID: 33655393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.
    Magnani CF; Turazzi N; Benedicenti F; Calabria A; Tenderini E; Tettamanti S; Giordano Attianese GM; Cooper LJ; Aiuti A; Montini E; Biondi A; Biagi E
    Oncotarget; 2016 Aug; 7(32):51581-51597. PubMed ID: 27323395
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fluorine-19 nuclear magnetic resonance of chimeric antigen receptor T cell biodistribution in murine cancer model.
    Chapelin F; Gao S; Okada H; Weber TG; Messer K; Ahrens ET
    Sci Rep; 2017 Dec; 7(1):17748. PubMed ID: 29255242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography.
    Sakemura R; Cox MJ; Bansal A; Roman CM; Hefazi M; Vernon CJ; Glynn DL; Pandey MK; DeGrado TR; Siegler EL; Kenderian SS
    J Vis Exp; 2022 Feb; (180):. PubMed ID: 35253798
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.